What is the share price of Cohance Lifesciences Ltd (COHANCE) today?
The share price of COHANCE as on 22nd May 2025 is ₹1080.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Cohance Lifesciences Ltd (COHANCE) share?
The past returns of Cohance Lifesciences Ltd (COHANCE) share are- Past 1 week: -0.20%
- Past 1 month: -11.08%
- Past 3 months: -11.90%
- Past 6 months: -16.57%
- Past 1 year: 74.12%
- Past 3 years: 106.99%
- Past 5 years: 571.95%
What are the peers or stocks similar to Cohance Lifesciences Ltd (COHANCE)?
The peers or stocks similar to Cohance Lifesciences Ltd (COHANCE) include:What is the market cap of Cohance Lifesciences Ltd (COHANCE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cohance Lifesciences Ltd (COHANCE) is ₹41336.38 Cr as of 22nd May 2025.What is the 52 week high and low of Cohance Lifesciences Ltd (COHANCE) share?
The 52-week high of Cohance Lifesciences Ltd (COHANCE) is ₹1360 and the 52-week low is ₹598.What is the PE and PB ratio of Cohance Lifesciences Ltd (COHANCE) stock?
The P/E (price-to-earnings) ratio of Cohance Lifesciences Ltd (COHANCE) is 137.66. The P/B (price-to-book) ratio is 20.16.Which sector does Cohance Lifesciences Ltd (COHANCE) belong to?
Cohance Lifesciences Ltd (COHANCE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Cohance Lifesciences Ltd (COHANCE) shares?
You can directly buy Cohance Lifesciences Ltd (COHANCE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Cohance Lifesciences Ltd
COHANCE Share Price
COHANCE Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
COHANCE Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
148.04 | 20.16 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.78 | 6.46 | 0.86% |
COHANCE Analyst Ratings & Forecast
Detailed Forecast from 6 analysts
Price Upside
Earnings Growth
Rev. Growth
COHANCE Company Profile
Cohance Lifesciences Limited is a technology-driven CDMO in India, offering custom synthesis, process R&D, and manufacturing services for pharmaceuticals and specialty chemicals.
Investor Presentation
View olderCOHANCE Similar Stocks (Peers)
Compare with peersCOHANCE Sentiment Analysis
COHANCE Stock Summary · November 2024
The company is strategically positioning itself for growth by focusing on compliance, transparency, and the integration of new technologies, particularly in the promising GLP-1 product space. With a robust 40% year-on-year growth in the Pharma CDMO segment, management is optimistic about future revenue, bolstered by positive clinical trial developments and a healthy order book. However, challenges persist, as evidenced by a decline in revenue during the first half of FY25, prompting a cautious approach to interpreting quarterly results. The upcoming merger with Cohance is anticipated to enhance growth prospects, while ongoing investments in capacity and strategic restructuring aim to improve visibility and operational performance. Overall, the company is navigating a dynamic market landscape with a focus on sustainable growth and customer engagement.
Key Points on Cohance Stock
COHANCE Stock Growth Drivers
7Strong Financial Performance
The company reported a year-on-year revenue increase of 12% in Q2 FY25, reaching Rs 2.58
Expansion of Product Pipeline
The company has significantly expanded its Phase-3 product pipeline, increasing the number of Phase-3 products
COHANCE Stock Challenges
4Revenue Decline
In the first half of FY25, the company experienced a significant revenue decline of 15.6%,
One-time Costs Impacting Margins
The company reported lower EBITDA margins due to one-time costs totaling Rs 52 million related
COHANCE Forecasts
COHANCE Forecast
Price
Revenue
Earnings
COHANCE Share Price Forecast
All values in ₹
All values in ₹
COHANCE Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
COHANCE Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
COHANCE
Income
Balance Sheet
Cash Flow
COHANCE Income Statement
Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 378.43 | 900.12 | 1,077.69 | 1,453.71 | 1,386.69 | 1,113.26 | 1,113.53 | |||||||
Raw Materials | 124.52 | 240.24 | 310.32 | 459.46 | 430.08 | 265.88 | 673.51 | |||||||
Power & Fuel Cost | 18.06 | 38.24 | 44.20 | 59.55 | 73.93 | 48.30 | ||||||||
Employee Cost | 29.63 | 65.10 | 76.23 | 100.48 | 118.25 | 135.92 | ||||||||
Selling & Administrative Expenses | 16.23 | 44.76 | 44.96 | 53.18 | 46.45 | 41.00 | ||||||||
Operating & Other expenses | 17.84 | 60.70 | 91.01 | 65.84 | 97.46 | 154.45 | ||||||||
EBITDA | 172.15 | 451.08 | 510.97 | 715.20 | 620.52 | 467.71 | 440.02 | |||||||
Depreciation/Amortization | 11.50 | 23.51 | 31.64 | 39.10 | 47.99 | 54.60 | 67.96 | |||||||
PBIT | 160.65 | 427.57 | 479.33 | 676.10 | 572.53 | 413.11 | 372.06 | |||||||
Interest & Other Items | 2.79 | 23.07 | 11.67 | 8.53 | 12.81 | 7.45 | 8.90 | |||||||
PBT | 157.86 | 404.50 | 467.66 | 667.57 | 559.72 | 405.66 | 363.16 | |||||||
Taxes & Other Items | 48.59 | 87.51 | 105.34 | 213.78 | 148.44 | 105.39 | 83.94 | |||||||
Net Income | 109.27 | 316.99 | 362.32 | 453.79 | 411.28 | 300.27 | 279.22 | |||||||
EPS | — | 24.91 | 14.23 | 17.83 | 16.16 | 11.80 | 10.97 | |||||||
DPS | 0.00 | 2.50 | 2.00 | 5.00 | 6.00 | 0.00 | 0.00 | |||||||
Payout ratio | — | 0.10 | 0.14 | 0.28 | 0.37 | 0.00 | 0.00 |
COHANCE Company Updates
COHANCE Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Cohance Lifesciences Ltd | 137.66 | 20.16 | — |
Sun Pharmaceutical Industries Ltd | 37.73 | 6.15 | 0.93% |
Cipla Ltd | 22.49 | 4.43 | 1.09% |
Torrent Pharmaceuticals Ltd | 56.89 | 15.86 | 1.00% |
COHANCE Stock Price Comparison
Compare COHANCE with any stock or ETFCOHANCE Shareholdings
COHANCE Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
COHANCE Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
COHANCE Shareholding Pattern
COHANCE Shareholding History
Mutual Funds Invested in COHANCE
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Cohance Lifesciences Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 1.53% | Change in the portfolio weight of the stock over the last 3 months -0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/53 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 62/536 (+28) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.00% | Change in the portfolio weight of the stock over the last 3 months -0.44% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/75 (-6) |
Compare 3-month MF holding change on Screener
smallcases containing COHANCE stock
Looks like this stock is not in any smallcase yet.
COHANCE Events
COHANCE Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
COHANCE Upcoming Dividends
No upcoming dividends are available
COHANCE Past Dividends
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateFeb 15, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Feb 15, 2022
COHANCE Stock News & Opinions
Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value of Re 1 each to the eligible shareholders of Cohance Lifesciences (transferor company) in share exchange ratio of 11:295 in terms of the scheme of amalgamation. Powered by Capital Market - Live
Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from 'Suven Pharmaceuticals' to 'Cohance Lifesciences', with effect from 07 May 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma.Powered by Capital Market - Live
Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench. In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions. The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.Powered by Capital Market - Live
Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live
Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under: Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications') Short Term Rating - CRISIL A1+ (Reaffirmed)Powered by Capital Market - Live
Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24. Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24. In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7% In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules. In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2. On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A. Vivek Sharma, executive chairman, commented, 'Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.' V. Prasada Raju, managing director, added: 'We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.' Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.Powered by Capital Market - Live
Suven Pharmaceuticals Ltd gained 5.19% today to trade at Rs 1099.95. The BSE Healthcare index is up 0.8% to quote at 41147.95. The index is down 4.33 % over last one month. Among the other constituents of the index, NGL Fine Chem Ltd increased 4.34% and Aurobindo Pharma Ltd added 4.1% on the day. The BSE Healthcare index went up 17.3 % over last one year compared to the 6.26% surge in benchmark SENSEX. Suven Pharmaceuticals Ltd has added 4.29% over last one month compared to 4.33% fall in BSE Healthcare index and 0.23% drop in the SENSEX. On the BSE, 2774 shares were traded in the counter so far compared with average daily volumes of 9706 shares in the past one month. The stock hit a record high of Rs 1359 on 02 Dec 2024. The stock hit a 52-week low of Rs 597 on 04 Jun 2024.Powered by Capital Market - Live
Net profit of Suven Pharmaceuticals rose 77.28% to Rs 82.88 crore in the quarter ended December 2024 as against Rs 46.75 crore during the previous quarter ended December 2023. Sales rose 39.73% to Rs 307.15 crore in the quarter ended December 2024 as against Rs 219.82 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales307.15219.82 40 OPM %38.3230.06 - PBDT130.0878.26 66 PBT109.7365.47 68 NP82.8846.75 77 Powered by Capital Market - Live
Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc. (target company), at an aggregate consideration of USD 64.4 million, which includes USD 15 million of primary equity infusion into the target company. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 24.09%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.17% to 0.29%
Over the last 5 years, net income has grown at a yearly rate of 22.41%, vs industry avg of 15.28%